NVNO

NVNO

enVVeno Medical Corp

Rev โ€”top 1%5Y
Hold

enVVeno Medical Corp develops bioprosthetic tissue-based solutions for venous disease treatment. Its primary products include the VenoValve, a surgical venous valve replacement, and the enVVe system, a non-surgical transcatheter valve replacement.

โš•๏ธ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 5 years ago โ†’$46today

Score Overview

1 Year
Scoreโ€”
Net Growth19.25%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth4.86%
Net Trend80%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
All Time
Score
Net Growth-20.56%
Net Trend63%
Net Income Consistency
Rev Growth-100.00%
Rev TrendNever
Revenue Consistency

See the full market ranking โ†’

enVVeno Medical Corp fundamental performance

Across enVVeno Medical Corp's full reported history, from 2018 to 2025, revenue declined from $ 186.55K to $ 0.00 and net income went from -$ 13M to -$ 19M. Revenue increased in 0% of the years measured; net income in 63%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 10.99โ€”
1 Year2025-08-12
$ 160.30-93.14%
5 Years2021-08-12
$ 237.30-95.37%
All Time2018-05-31
$ 4.58K-99.76%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 15M$ 21M
2025$ 0.00-$ 19M$ 28M
2024$ 0.00-$ 21M$ 43M
2023$ 0.00-$ 23M$ 46M
2022$ 0.00-$ 24M$ 39M
2021$ 0.00-$ 16M$ 54M
2020$ 0.00-$ 9M$ 9M
2019$ 31.24K-$ 7M$ 1M
IPO2018$ 186.55K-$ 13M$ 2M

Explore beyond NVNO

You're looking at enVVeno Medical Corp. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies